Insider Selling: Seer (NASDAQ:SEER) CFO Sells $14,837.27 in Stock

Seer, Inc. (NASDAQ:SEER – Get Free Report) CFO David Horn sold 7,309 shares of Seer stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $2.03, for a total transaction of $14,837.27. Following the completion of the sale, the chief financial officer directly owned 486,650 shares in the company, valued at approximately $987,899.50. This represents a 1.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Seer Stock Up 0.5%

SEER opened at $2.03 on Friday. Seer, Inc. has a twelve month low of $1.55 and a twelve month high of $2.41. The company’s 50-day moving average price is $1.99 and its two-hundred day moving average price is $1.89. The stock has a market cap of $111.61 million, a price-to-earnings ratio of -1.66 and a beta of 1.56.

Get Seer alerts:

Seer (NASDAQ:SEER – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Seer had a negative return on equity of 27.23% and a negative net margin of 478.05%.The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.55 million.

Hedge Funds Weigh In On Seer

Several large investors have recently modified their holdings of SEER. Occudo Quantitative Strategies LP bought a new stake in shares of Seer in the second quarter valued at approximately $25,000. Marshall Wace LLP bought a new position in Seer in the 4th quarter worth approximately $85,000. Quadrature Capital Ltd bought a new position in Seer in the 4th quarter worth approximately $101,000. Marquette Asset Management LLC bought a new position in Seer in the 2nd quarter worth approximately $103,000. Finally, Barclays PLC grew its stake in Seer by 685.0% in the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after buying an additional 52,982 shares in the last quarter. Hedge funds and other institutional investors own 75.20% of the company’s stock.

Analyst Ratings Changes

SEER has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Seer in a research report on Friday, July 17th. Canaccord Genuity Group initiated coverage on Seer in a research report on Monday, May 4th. They set a “buy” rating and a $4.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $4.00.

Check Out Our Latest Report on Seer

Seer Company Profile

(Get Free Report)

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.

Featured Articles

• Five stocks we like better than Seer
• Blueprint for a Boom: SEC Clears the Crypto Runway
• Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
• Advance Auto Parts Plunged, But Its Turnaround Is Still Working
• Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.